EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... [Yahoo! Finance]
EyePoint, Inc. (EYPT)
Last eyepoint, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Net Revenue from Royalties and Collaborations (Q4 2024): $10.8 million, compared to $13.3 million in Q4 2023. Operating Expenses (Q4 2024): $56.8 million, compared to $30.4 million in Q4 2023. Net Loss (Q4 2024): $41.4 million or $0.64 per share, compared to $14.1 million or $0.33 per share in Q4 2023. Total Net Revenue (Full Year 2024): $43.3 million, compared to $46 million in 2023. Net Product Revenue (Full Year 2024): $3.2 million, compared to $14.2 million in 2023. Net Revenue from Royalties and Collaborations (Full Year 2024): $40.1 million, compared to $31.8 million in 2023. Operating Expenses (Full Year 2024): $189.1 million, compared to $121.1 million in 2023. Net Loss (Full Year 2024): $130.9 million or $2.32 per share, compared to $70.8 million or $1.82 per share in 2023. Cash and Investments (End of 2024): $371 million, compared to $331 million at the end of 2023. Warning! GuruFocus has detected 5 Warning Signs with EYPT. Release Date: March 05, 2025
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- EyePoint to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 11/5/25 - Miss
EYPT
Sec Filings
- 12/8/25 - Form SCHEDULE
- 12/8/25 - Form 4
- 12/8/25 - Form 8-K
- EYPT's page on the SEC website